# AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05904379/  
OnCo record `nct05904379` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ivonescimab, Cadonilimab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, active and no longer recruiting.

## Summary

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05904379 by Akeso, with 233 participants planned, started 2023-07-13 and due to reach its primary completion in 2026-06-30. Interventions recorded: AK112, AK104, Carboplatin, paclitaxel, pemetrexed. Conditions listed: Advanced Non-small-cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05904379
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial of AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
- Sponsor: Akeso
- Enrolled: 233

## Sources

- ClinicalTrials.gov NCT05904379: https://clinicaltrials.gov/study/NCT05904379

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct05904379.json